MLTX - MoonLake Immunotherapeutics Latest News | Finranks

MLTX - MoonLake Immunotherapeutics Latest News | Finranks

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

ZUG, Switzerland, March 28, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces long-term Week 40 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational global program in patients with moderate-to-severe HS and confirms the presentation of the data at the 2026 American Academy of Dermatology (AAD) Annual Meeting later today.

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?

Cormorant Asset Management increased its MoonLake Immunotherapeutics position by 2,361,260 shares in the fourth quarter; the estimated trade value is $27.86 million based on average quarterly prices. The quarter-end value of the stake rose by $43.11 million, a figure reflecting both trading activity and stock price movement.

MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal

MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal

MoonLake Immunotherapeutics is downgraded from Strong Buy to Buy following a mixed phase 3 outcome for sonelokimab in hidradenitis suppurativa [HS]. Despite VELA-2's primary endpoint miss, the FDA's positive Type B meeting allows MLTX to file a BLA for HS using existing VELA-1, VELA-2, and MIRA data. MLTX advances sonelokimab in multiple inflammatory indications, with strong phase 2 axSpA results [81% ASAS40 at Week 12] and upcoming phase 3 PsA data in 2026.

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain

MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain

Axial Spondyloarthritis is a chronic, immune-mediated inflammatory disease mainly affecting the spine and sacroiliac joints, often causing chronic back pain, stiffness, and potential spinal fusion.

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be focused on driving execution of the Phase 2b ADAPTIVE trial in atopic dermatitis (AD) and building Imagene's clinical organization.

BioTech Breakout: MoonLake Up 30% On FDA Wins

BioTech Breakout: MoonLake Up 30% On FDA Wins

In a stock market currently obsessed with interest rate cuts and the artificial intelligence (AI) boom, it is easy to overlook the biotechnology sector. However, for investors willing to look beyond the Magnificent Seven, clinical-stage biotech remains one of the few places to find massive, event-driven returns that are largely independent of the broader economy.

Videos

No Data

There is no data to display